New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer

Improved survival in a phase 3 trial where the new drug was added onto chemotherapy could move immunotherapy to the first line, say experts.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Nasopharyngeal carcinoma is a malignancy that is endemic in Asia. The current standard of care for loco-regionally advanced disease is platinum-based concurrent chemo-radiotherapy. However, relapse remains a common issue. Phase II trials have shown encouraging results when induction chemotherapy with gemcitabine and cisplatin is added to chemo-radiation. In a major recent advance, a phase III trial demonstrated significantly improved recurrence-free survival (RFS) and overall survival (OS) for this approach compared to chemo-radiotherapy alone. Results from this trial showed a 4.3% improvement in OS over standard therapy a...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Reviews Source Type: research
Opinion statementStandard-of-care treatment for the majority of patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) is either upfront surgery followed by adjuvant treatment as indicated by intraoperative or pathologic findings or concurrent chemoradiation reserving surgical salvage for non-responsive disease. An attempt at upfront complete resection should be pursued if feasible in patients with oral cavity or paranasal sinus primary tumors. Given multimodality treatment paradigms, patients with locoregionally advanced SCCHN should be managed in a multidisciplinary setting. Modern rad...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: The data presented show promising approaches for the further development of radiotherapy, particularly in terms of combined RCT as well as the optimal sequencing and dosing of systemic therapies. PMID: 31659379 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Abstract Many of the principles established in adults with undifferentiated nasopharyngeal carcinoma (NPC) apply to children, adolescents and young adults (AYA). However, NPC in young patients should be distinguished from the adult form by several points. This review focuses mainly on differences between adult and pediatric NPC. The role of biology and genetics in pediatric NPC is discussed. Systemic treatment modalities including type of chemotherapy induction, timing of treatment, role of immunotherapy as adjuvant treatment, or in relapsing/ metastatic diseases are reported. Radiation modalities (doses, techniqu...
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
ConclusionIncreased cytotoxicity of NK cells against NPC cells and increased serum levels of biologically active TRAIL in patients treated with IFN β could be a means to eliminate micrometastatic disease and explain the low systemic relapse rate in this patient group.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
AbstractHead and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of pa...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
AbstractRecent phase 1 –2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lackin g. We aimed to comprehensively compare the efficacy and safety of different anti-PD-1 drugs, standard chemotherapy, and their combination therapy in RM-NPC. Adverse event (AE) and objective response rate (ORR) were assessed. The pooled incidence rates of grade 1–5/3–5 AEs were 74.1%/29.6, ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, the immunohistochemistry results demonstrated that DEPDC1 was high-expressed in breast cancer tissues compared with the paired adjacent normal breast tissues, and its tendency at protein level was consistent with mRNA level from TCGA data. Moreover, DEPDC1 mRNA level revealed the strongest association with poor prognosis and development in breast cancer. In vitro assays showed that DEPDC1 overexpression resulted in significant promotion of proliferation by regulating cell cycle in MCF-7 cells, whilst an opposite effect was found in the MDA-MB-231 cells with DEPDC1 deletion. Notably, further investigation ind...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Nasopharyngeal carcinoma (NPC) is one of the head and neck cancers with high incidence in Southeast Asia, and is connected with Epstein –Barr virus (EBV) infection [1]. Intensity-modulated radiotherapy (IMRT) alone or in combination with chemotherapy, targeted therapy, and immunotherapy is the main treatment for non-metastatic NPC, achieving good disease-free survival and overall survival (OS) [2,3]. But NPC tends to relapse and/o r metastase after definitive treatment [4,5]. Therefore, NPC patients, who develop local recurrence or distant metastases after treatment, require more intensive follow-up and effective treatment strategies.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Nasopharyngeal Cancer